Stay updated with breaking news from Precise Tumor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven
Molecular Residual Disease study and multiple RiskScore studies among seven new datasets to be shared by Myriad and Collaborators SALT LAKE CITY, May 23, 2024 -- Myriad Genetics, Inc., , a leader...
Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2023 Earnings Call Transcript February 27, 2024 Myriad Genetics, Inc. beats earnings expectations. Reported EPS is $0.04, expectations were $0.02. Myriad Genetics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and welcome […]
Company Raises 2024 Revenue Guidance and Delivers Positive Adjusted EPS in Q4
SALT LAKE CITY, Feb. 01, 2024 -- Myriad Genetics, Inc., , a leader in genetic testing and precision medicine, today announced it has completed the acquisition from Intermountain Health of select...